Lunchtime fringe panel discussion
- sponsored by Dexcom
We would like to invite you to an additional lunchtime panel session, taking place at the conference, called Where does continuous glucose monitoring (CGM) fit in type 2 diabetes care in the UK?
This session is being sponsored by Dexcom and will take place during the scheduled lunchbreak from 12:15pm to 1:25pm.
The full lunch menu will be provided to all attendees outside the session room.
There is no need to book this session in advance. Places at the session will be distributed on a first come, first served basis.
What will be discussed?
Across Europe, several health systems have progressively broadened access to CGM in type 2 diabetes, extending beyond high risk intensive insulin treated populations to include people using basal insulin, often to support treatment optimisation, behaviour change and safer intensification. In comparison, current UK guidance remains relatively narrow, with CGM largely recommended for people with type 2 diabetes on multiple daily insulin injections who meet specific high-risk criteria, leaving limited structured access for the wider insulin treated population.
At the same time, NICE’s ongoing medicines update signals a fundamental shift in type 2 diabetes management, with earlier use of SGLT2 inhibitors and GLP 1 receptor agonists based on comorbidity and prevention of long-term outcomes. This evolving therapeutic landscape raises important questions including what are the potential challenges in using this tech for type 2 diabetes?
Chair: Ben McNally, deputy head of MedTech, Costello.
Panellists:
- Prof Naresh Kanumilli, GP and Diabetes UK clinical champion, Manchester University NHS Foundation Trust and chair of the diabetes board for Greater Manchester
- Jaivir Pall, board member, International Diabetes Federation (IDF)
- Thomas Lambert, healthcare engagement and systems change manager north of England, Diabetes UK
- Eric Power, interim director, centre for guidelines, NICE.